SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 5, 2004

TecScan International, Inc.
---------------------------
(Exact name of small business issuer as specified in its charter)

Nevada 000-30546 33-0714007
- ------ --------- ----------
(State or other jurisdiction Commission File Number (I.R.S. Employer
of incorporation or organization) Identification No.)

117 East Louisa Street, Suite 104 Seattle, Washington 98102
-----------------------------------------------------------
(Address of principal executive offices)

(310) 722-9914
--------------
(Issuer's Telephone Number)

ITEM 1. CHANGES IN CONTROL OF REGISTRANT.

On April 5, 2004, we purchased 35,000,000 common shares representing all of the
issued and outstanding shares of common stock of Bio-Life Laboratories
Corporation, pursuant to that certain Stock Purchase Agreement and Plan of
Reorganization (the "Agreement and Reorganization") dated April 5, 2004, between
TecScan International, Inc., and Bio-Life Laboratories Corporation, a
privately-held Nevada corporation ("Bio-Life"), pursuant to which we are
acquiring Bio-Life as our wholly-owned subsidiary. As of the date of this
report, Bio-Life's sole product is "Carcinoderm", an ointment, described more
fully below.

Under the Agreement and Reorganization we are required to change our name to
Bio-Life Labs, Inc. and the OTCBB symbol under which our common stock trades on
the Over-The-Counter Bulletin Board as soon as practicable following the filing
of this report. Our common stock now trades on the Over-The-Counter Bulletin
Board under the OTCBB symbol "TSCN."

As a result of the Agreement and Reorganization, we issued a total of 35,000,000
restricted shares of common stock to the shareholders of Bio-Life in exchange
for all the outstanding shares of Bio-Life, which also totaled 35,000,000
shares, with Nancy LeMay as Trustee for those shareholders. Ms. LeMay has sole
voting power as to the 35,000,000 shares, though dispositive power remains with
the original Bio-Life shareholders. Those shares will be distributed to the
Bio-Life shareholders as the reorganization is given effect. As a result of this
transaction, the Registrant's total issued and outstanding shares of common
stock is 47,091,805. The 35,000,000 shares of common stock of the Registrant's
common stock issued as a result of the Agreement and Reorganization represents
approximately 74.3% of the voting securities of the Registrant.

On April 8, 2004, Philip T. Kueber resigned his offices as President, Secretary,
Treasurer and Director and thereafter appointed Nancy LeMay, David Karam M.D.,
PhD. and Joseph McGhie, LL.B., M.B.A. to fill the vacancies on the Board of
Directors. Ms. LeMay was also elected President and Secretary of the Registrant.

SECURITY OWNERSHIP OF BENEFICIAL OWNERSHIP AND MANAGEMENT

The following table sets forth certain information regarding the beneficial
ownership of our common stock as of April 8, 2004, by each person or entity
known by us to be the beneficial owner of more than 5% of the outstanding shares
of common stock, each of our directors and named executive officers, and all of
our directors and executive officers as a group.

Title of Class Name and Address of Beneficial Owner Amount and Nature of Beneficial Percent of
Owner Class
- ------------------------ --------------------------------------- ------------------------------------ --------------

Common Stock Nancy LeMay(1) 35,000,000 shares 74.3%
117 East Louisa Street, Suite 104 President, Secretary, Director
Seattle, Washington 98102

Common Stock David Karam, M.D., Ph.D No shares 0%
117 East Louisa Street, Suite 104 Director
Seattle, Washington 98102

Common Stock Joseph McGhie, LL.B, M.B.A. No shares 0%
117 East Louisa Street, Suite 104 Chief Financial Officer,
Seattle, Washington 98102 Director

Common Stock All directors and named executive 35,000,000 shares 74.3%
officers as a group

(1) Ms. LeMay is the Trustee for shares held by the Bio-Life shareholders,
which will be distributed as the reorganization is given effect.

Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission and generally includes voting or investment
power with respect to securities. In accordance with Securities and Exchange
Commission rules, shares of our common stock which may be acquired upon exercise
of stock options or warrants which are currently exercisable or which become
exercisable within 60 days of the date of the table are deemed beneficially
owned by the optionees. Subject to community property laws, where applicable,
the persons or entities named in the table above have sole voting and investment
power with respect to all shares of our common stock indicated as beneficially
owned by them.

The Registrant is not aware of any arrangements which may result in "changes in
control" as that term is defined by the provisions of Item 403 of Regulation
S-B.

DIRECTORS AND EXECUTIVE OFFICERS

The following tables set forth information regarding the Registrant's current
executive officers and directors:

============================= ============= ===================================
Name Age Position
----------------------------- ------------- -----------------------------------
Nancy LeMay 41 President, Secretary and Director
----------------------------- ------------- -----------------------------------
David Karam 38 Director
----------------------------- ------------- -----------------------------------
Joseph McGhie 51 Director
============================= ============= ===================================

NANCY LEMAY. On April 8, 2004, Ms. LeMay was appointed as President, Secretary
and as a member of our Board of Directors.LeMay is also the president and a
director of Bio-Life Labs, Inc. An entrepreneur and business leader for over 20
years, Ms LeMay has been active in the concept design, launch, and operation of
start-up businesses facing break-in market and rapid expansion challenges,
including gaming, construction components manufacturing, insurance product and
program design, and healthcare corporate finance.

Ms. LeMay began her career with the Internal Revenue Service ("IRS"), where she
rose through the ranks as a Revenue Officer and Revenue Agent, acting finally as
Chief of Special Procedures where she advised Examination and Collection
Division personnel regarding the highly specialized, technical and complex
aspects of Federal taxation, including insolvencies, trusts and decedent
estates, Federal Tax Lien issues, transferee and jeopardy assessments, and
redemption rights. During her employment with the IRS, Ms. LeMay completed
extensive coursework in personal, corporate, and estate and trust taxation. Ms.
LeMay was also a frequent Regional Lead Instructor for Revenue Officer and
Revenue Agent training programs.

Following her IRS service, Ms. LeMay joined the State of Nevada's Gaming Control
Board as a Financial Agent, performing complex financial investigations of
corporate gaming license applicants, and presenting transaction and other
financial analysis to Board members for application determination. Since leaving
government service, Ms. LeMay has been both a consultant to and involved in the
senior management of early stage businesses, bringing concepts to commercial
reality by working with investors and lenders, other executives, and customers
within service, manufacturing, and retail industry sectors. Ms. LeMay was
educated at the University of Nevada at Reno, where she studied accounting. Ms.
LeMay is not an officer or director or director of any other reporting company.

DAVID KARAM, M.D., Ph.D. As of April 8, 2004, Dr. Karam was appointed as a
member of our Board of Directors. Dr. Karam is Executive Vice President and
Chief Medical Officer, and a member of the Board of Directors of Bio-Life Labs,
Inc. In his role as Executive Vice President and Chief Medical Officer Dr. Karam
is responsible for Bio-Life's Medical Affairs, Regulatory Affairs, Research and
Product Development, Development Sciences, and Quality functions. Prior to
joining Bio-Life Labs, Dr. Karam was the Director of Scientific Research for ZDS
Center for Human Performance and Biotechnology Labs, L.L.C. in El Paso, Texas.
While at ZDS, Dr. Karam's research was centered on developing an adjunctive
treatment for Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma skin
cancers. Dr. Karam's 10-year career in medical research included a focus on CNS
regenerative work and receptive field expansion; his research in these areas
resulted in the development of a spinal fusion device as well as a publication
on the efficacy of implantable spinal stimulation and it's efficacy for the
control of intractable pain. In earlier years Dr. Karam was a volunteer
assistant through Emory University with the Center for Disease Control in the
research of the Ebola virus; he also assisted on the Necrotizing Fascitis
projects.

In addition to his work at Bio-Life Labs, Dr. Karam holds a board position
with the St. Luke School of Medicine where he is the Director of Doctoral
Programs and Adjunct Professor in Neurosciences. He has also served as an
Adjunct Professor in the Physical Therapy Program with El Paso Community
College, where he wrote the class text; developed the examination material; and
taught Functional Anatomy as well as the Board Review Class for the Physical
Therapist Assistant State licensure exam. Dr. Karam was a lead instructor in a
course entitled Microsurgical Management of Carpal Tunnel Syndrome, taught in
conjunction with the University of Juarez, Mexico, and in earlier years taught
as a Graduate Assistant in Organic Chemistry under the direction of Dr. Jack
Duff at Kennesaw State University.

Dr. Karam has published two textbooks: Gross Anatomy of the Head and Neck, and
Neuroscience - a New Horizon. He has presented papers to the Music Therapy
Association in the Anatomic Basis of Hearing and Music Association, and on the
Anatomic Basis of Evoked Emotion and the Neuro-Anatomic Basis of Music; to the
Chemistry Society on the Utilization of NMR for the Identification of 3D
molecular structures; to the Athletic Trainers Association of Texas on
Concussion and the Neurophysiologic basis of Concussive Syndrome; and has made
additional scientific presentations on Steroids and Sports Medicine to the Ohio
Chapter of the American Physical Therapy Association, and Receptive Field

Expansion at Emory University. Dr. Karam developed a computer program for the
containment of possible Chemical Weapons of Mass Destruction in conjunction with
Daniels and Associates of Phoenix, Arizona. Dr. Karam is a member of the
American Chemical Society; the International Brain Research Organization; the
Cognitive Neuroscience Society; the Royal Society of Neuroscience; the American
Physiology Society; the American Academy of Anti-aging; the American Academy of
Neurological Surgeons; and the American Academy of Orthopedic and Neurologic
Surgeons. In 2004 Dr. Karam was listed in the Empire Who's Who. Dr. Karam holds
a Bachelor of Science degree in Business Management and received his Doctor of
Medicine degree from St. Luke School of Medicine; he completed post-doctoral
work in Neuroscience and Biochemistry. Dr. Karam is not an officer or director
of any other reporting company.

JOSEPH G. MCGHIE. LL.B, M.B.A. As of April 8, 2004, Mr. McGhie was appointed as
a member of our Board of Directors. Mr. McGhie is also our Chief Financial
Officer. Mr. McGhie is an experienced investment banking and corporate finance
dealmaker, having initiated and completed transactions valued at more than
$750,000,000. Mr. McGhie has been active in arranging sale, finance, merger, and
strategic alliance transactions since 1974, and has specialized in assisting
early stage and middle market companies in California, Nevada and Arizona since
1985. A frequent speaker at industry and community associations, we believe Mr.
McGhie is known for developing creative solutions to complex and challenging
corporate finance situations. His expertise includes identifying equity
investors for private, high growth companies, creating innovative capital
structures, and arranging mergers, acquisitions, strategic partnerships and
alliances.

As a strong supporter of graduate level education, Mr. McGhie has been involved
with the Anderson Graduate School of Business Administration, The University of
Southern California, University of Nevada Las Vegas, and Harvard Business School
Association in Orange County and Los Angeles. Mr. McGhie holds a Bachelor of
Laws degree (LL.B.) from the University of Alberta, Canada and an MBA with
Second Year Honors from the Harvard Business School. Mr. McGhie is not an
officer or director of any other reporting company.

There is no family relationship between any of our officers or directors. There
are no orders, judgments, or decrees of any governmental agency or
administrator, or of any court of competent jurisdiction, revoking or suspending
for cause any license, permit or other authority to engage in the securities
business or in the sale of a particular security or temporarily or permanently
restraining any of our officers or directors from engaging in or continuing any
conduct, practice or employment in connection with the purchase or sale of
securities, or convicting such person of any felony or misdemeanor involving a
security, or any aspect of the securities business or of theft or of any felony.
Nor are any of the officers or directors of any corporation or entity affiliated
with us so enjoined.

ITEM 2. ACQUISITION OF ASSETS. Pursuant to the Agreement and Reorganization, we
are acquiring Bio-Life as our wholly-owned subsidiary: the Registrant (i) issued
35,000,000 shares of its Registrant's common stock to Nancy LeMay as Trustee for
the shareholders of Bio-Life; (ii) appointed Nancy LeMay as the President,
Secretary and a director of the Registrant, and David Karam and Joseph McGhie as
directors of the Registrant; and (iii) accepted the resignation of its current
management and cancelled the 35,000,000 shares held by the outgoing management
in exchange for 5,000,000 shares of Very Basic Media, Inc., which were owned by
the Registrant. As a result of these transactions, the Registrant's total issued
and outstanding shares of common stock is 47,091,805. Under the terms of the
Agreement and Reorganization, the Registrant will assume undertake the business
of Bio-Life, as described below.

BIO-LIFE LABORATORIES CORPORATION. Bio-Life Laboratories Corporation was formed
in Nevada in 2003 to facilitate the introduction of Carcinoderm, an ointment
that has been used to successfully treat skin cancer patients with Basal Cell
Carcinoma, Squamous Cell Carcinoma, and Melanoma in FDA-conforming clinical
trials. Dr. David Karam, who has been appointed as one of the Registrant's
directors, developed and is conducting clinical trials of Carcinoderm in his
laboratory, The Center for Human Performance and Biotechnology Laboratories,
L.L.C. in El Paso, Texas, where he is currently investigating other possible
uses of and delivery systems for Carcinoderm in the treatment of other types of
cancer, including tumors of the pancreas and brain, as well as developing new
treatments for Diabetes Mellitus and Hepatitis C. We have the right of first
refusal on Dr. Karam's products that are being designed to treat Diabetes
Mellitus and Hepatitis C, but do not have rights to them at this time.

THE PRODUCT. Carcinoderm is a topical ointment made from FDA-approved
ingredients that we believe destroys skin cancer cells in a one-time application
without harming surrounding healthy tissue. After the ointment has been applied
to the affected area, a scab begins to form. In four to five weeks the scab
falls off, leaving the underlying tissue in a hypersensitive state for
approximately 48 hours. Skin coloration returns to normal after seven or eight
weeks. At the 12-week mark, there is little evidence of tissue alteration and
the treated area has totally returned to its previous thickness.

PRODUCT CLASSIFICATION AND REGULATION. Carcinoderm is made from plant material
and other FDA-approved ingredients. Although Carcinoderm is classified as a
nutraceutical, and thus does not require FDA approval, Dr. Karam has followed
FDA guidelines, rules, and regulations applicable to a clinical research project
to prepare for application for FDA approval for this product (a product need not
be classified as a pharmaceutical to receive FDA approval), as well as to
document its efficacy. When Dr. Karam applies for Phase I FDA approval process,
his FDA-conforming clinical trial records are in place.

PRODUCT FEATURES. We believe that the efficacy factor for Carcinoderm rivals
other forms of skin cancer treatments, but with significant advantages:

|X| One-time application.
|X| No residual disfigurement.
|X| Does not harm surrounding healthy tissue.

In the estimation of our management, the product also appears to act as a
diagnostic tool. When Carcinoderm is applied to a cancer lesion, a pattern of
red-colored finger projections radiate out from the treated area; these
projections appear to be underlying cancer cells. Because the product does not
attack healthy tissue, these finger projections do not appear when it is applied
to a benign lesion.

PRODUCTION. Dr. Karam is currently producing the Carcinoderm ointment in a
three-step segmented production process in his own labs in El Paso and Juarez,
and the local college. The first step in production is an extraction procedure
from a group of plants. In a second step, the extracted material is heated in
large ovens. The third and final step is mixing the product and putting it in
plastic containers. Dr. Karam plans to produce the product in single-tube
applications with a peel-off top. While production of larger tubes is still
under consideration, Dr. Karam prefers the one-application tube because of shelf
life as well as re-engineering issues. One application of Carcinoderm measures
approximately 0.5 grams.

CLINICAL TRIALS. Although Dr. Karam has not formally applied for FDA approval,
he has been conducting clinical trials of Carcinoderm in compliance with FDA
rules for almost two years in order to document treatment results of the product
in accordance with standards acceptable to qualified evaluators of the product,
and to establish its efficacy for health care professionals. When Dr. Karam
applies for FDA approval for the product or a derivation of the product, we
believe that qualified FDA Phase I studies will already be in place.

THE MARKET. In the estimation of our management, the world's most common
malignancy is cancer of the skin, and that between 2 and 3 million non-melanoma
skin cancers, and 132,000 melanoma skin cancers occur globally each year. One in
every three cancers diagnosed is a skin cancer and, according to Skin Cancer
Foundation Statistics, one in every five Americans will develop skin cancer in
their lifetime. Indeed, we believe that skin cancer is the most widespread form
of cancer in the population of the United States, surpassing the incidence of
all other forms of cancer combined. In 2002 over 1.3 million people in this
country were diagnosed with various types of skin cancers; in the estimation of
our management, that number is expected to increase by two percent for the year
2003, and continue to rise due to an increasing elderly population, changes in
outdoor leisure activities, the prevalence of immunosuppressive therapy, and
failure to use sunscreens. An additional concern is the gradual depletion of
ozone levels. It is estimated that a 10 per cent decrease in ozone levels will
result in an additional 300,000 non-melanoma and 4,500 melanoma skin cancer
cases.

According to information compiled by our management, the cost to Medicare for
the treatment of skin cancers in the United States is currently estimated at $
13 billion per year. That figure, based on an analysis of CPT codes in a 5%
cross section of the Medicare billing database, approaches the total cost to
treat both prostate and breast cancer. While the incidence of breast and
prostate cancers has remained relatively stable, diagnoses of skin cancers
continue to rise. Reports of this phenomenon appear worldwide, however, tracking
global treatment costs presents severe logistical challenges because of problems
relating to reporting and lack of uniformity in the registry of skin cancer
statistics.

RESEARCH AND DEVELOPMENT.

Carcinoderm: The Double Blind randomized clinical trial to test the efficacy of
Carcinoderm in the treatment of Squamous Cell Carcinoma, Basal Cell Carcinoma,
and Malignant Melanoma is ongoing. Additional research goals for 2004 with
respect to Carcinoderm are as follows:

|X| Define which receptor provides the intake for the Carcinoderm.
|X| Define the metabolic pathway for the activation of Carcinoderm.
|X| Define the long-term ramifications to tissue treated with Carcinoderm.
|X| Define which receptor is involved in the transference of the effects of
Carcinoderm from cell to cell, yet spares healthy tissue.
|X| Define possible uses of Carcinoderm in the treatment of other types of
tumor cells.

Other Treatment Products and Methods: Dr. Karam has developed treatment formulas
that we believe appear to be effective in initial research for treating Diabetes
Mellitus and Hepatitis C. We have the right of first refusal on these products
being designed by Dr. Karam to treat Diabetes Mellitus and Hepatitis C, but do
not have rights to them at this time. Research goals for 2004 with respect to
these treatments are as follows:

|X| Identify the mechanism of action/efficacy for the effects of the
nutraceutical formulation for Diabetes Mellitus.
|X| Identify the mechanism of action/efficacy for the effects of the
nutraceutical treatment for Hepatitis C.

PATENT. We anticipate that Dr. Karam will apply for at least six patents for
Carcinoderm to avoid product re-engineering; each patent will represent a
different production step. Since there are no publications of formula or
production process, we believe that there will not be a "public domain" issue.
As of the date of this filing, Dr. Karam has submitted a provisional patent
application for Caricinoderm.

RISKS. There are several risks typically associated with operations of this
type, and the Registrant cannot guarantee it will achieve the ability to operate
profitably. As a result of this transaction, the Registrant undertakes to
disclose in its upcoming annual report, a description of risks inherent in
operating its business, including product development, clinical trials, FDA
approval, physician and patient acceptance, development and manufacture and
sales of a marketable product, intellectual property and product liability.

ITEM 6. RESIGNATIONS OF REGISTRANT'S DIRECTORS. On April 8, 2004, Philip T.
Kueber resigned as the President, Secretary and director of the Registrant
pursuant to the terms of the Agreement and Reorganization referenced herein. The
resignation is not the result of any disagreement with the registrant on any
matter relating to the Registrant's operations, policies or practices. A copy of
Mr. Kueber's resignation is filed as Exhibit 17.1 to this Form 8-K.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
The financial information required by this Item will be filed by amendment no
later than 75 days following the closing date of the Agreement and
Reorganization.

INDEX TO EXHIBITS
- -----------------

10.1 Stock Purchase Agreement and Plan of Reorganization with Bio-Life
Laboratories Corporation

17.1 Resignation of Philip T. Kueber

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

TecScan International, Inc.

April 16, 2004 By: /s/ Nancy LeMay
------------------------------------
Nancy LeMay
President, Secretary and a director